Establishment of Personalized Cancer Medicine Using Samsung Cancer Sequencing Platform in Lung Cancer/Mediastinal Tumor/ Head & Neck/Esophageal Cancer/Rare Cancer (PerSeq: Personalized Sequence)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lung Cancer
- Sponsor
- Samsung Medical Center
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- the spectrum of targetable genetic mutation in evaluated cancer specimens (for example, % of EGFR T790M mutation, BRAF mutation, or ALK mutation)
- Last Updated
- 5 years ago
Overview
Brief Summary
The next generation of personalized medical treatment according to the type of personal genetic information are evolving rapidly. The genome analysis needs systematic infra and database based on personal genetic information Therefore, a big data of genome-clinical information is important.
Detailed Description
To determine the feasibility of the use of tumor's molecular profiling and targeted therapies in the treatment of advanced cancer and to determine the clinical outcome(PFS, duration of response and overall survival) of patients with advanced cancer, the investigators are going to take a fresh tissue of patients and process molecular profiling.
Investigators
Keunchil Park
Professor
Samsung Medical Center
Eligibility Criteria
Inclusion Criteria
- •metastatic, histologically confirmed NSCLC, head \& Neck Cancer, Esophageal cancer
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
the spectrum of targetable genetic mutation in evaluated cancer specimens (for example, % of EGFR T790M mutation, BRAF mutation, or ALK mutation)
Time Frame: 3 years
The pattern of the tumor's molecular profiling in advanced thoracic (lung, esophagus, or tthymic) cancer